靶向碳酸酐酶IX的放射性药物在
肾透明细胞癌及其他乏氧
肿瘤中的研究进展

doi:10.12677/acm.2026.1631042

期刊菜单

靶向碳酸酐酶IX的放射性药物在肾透明细胞癌及其他乏氧肿瘤中的研究进展
Research Progress of CAIX-Targeted Radiopharmaceuticals in Clear Cell Renal Cell Carcinoma and Other Hypoxic Tumors

DOI: 10.12677/acm.2026.1631042, PDF,
作者: 肖尧峰, 蔡亮^*：重庆医科大学附属第二医院核医学科，重庆
关键词: 碳酸酐酶IX；乏氧肿瘤；肾透明细胞癌；放射性药物；综述；Carbonic Anhydrase IX； Hypoxic Tumors； Clear Cell Renal Cell Carcinoma； Radiopharmaceuticals； Review

摘要: 乏氧是多数实体肿瘤(如肺癌、宫颈癌、胰腺癌、胶质母细胞瘤等)的共性特征，由肿瘤快速增殖与血管新生异常、血供灌注不足或物理屏障阻碍氧输送等因素导致，会激活乏氧诱导因子(HIF)信号通路驱动肿瘤恶性进展，与患者不良预后密切相关。碳酸酐酶IX (CAIX)是一种含锌的跨膜蛋白，其表达主要受HIF调控，在正常组织中分布极少，而在肾透明细胞癌等多种实体肿瘤的乏氧微环境中呈高度特异性高表达。因此CAIX成为多种乏氧肿瘤诊断和治疗的潜在靶点，本文就近年来靶向CAIX的放射性药物研究进行归纳总结，以期为临床相关疾病诊断提供新思路。

Abstract: Hypoxia is a common characteristic of most solid tumors, including lung cancer, cervical cancer, pancreatic cancer, and glioblastoma. It is caused by factors including rapid tumor proliferation, abnormal angiogenesis, insufficient blood perfusion, or physical barriers impeding oxygen delivery, and can activate the hypoxia-inducible factor (HIF) signaling pathway to drive the malignant progression of tumors, which is closely associated with poor prognosis in patients. Carbonic anhydrase IX (CAIX) is a zinc-containing transmembrane protein, whose expression is mainly regulated by HIF. It is barely distributed in normal tissues, but exhibits highly specific overexpression in the hypoxic microenvironment of various solid tumors such as clear cell renal cell carcinoma. Therefore, CAIX has become a potential target for the diagnosis and treatment of various hypoxic tumors. This article summarizes the research progress of CAIX-targeted radiopharmaceuticals in recent years, aiming to provide new ideas for the clinical diagnosis of related diseases.

文章引用：肖尧峰, 蔡亮. 靶向碳酸酐酶IX的放射性药物在肾透明细胞癌及其他乏氧肿瘤中的研究进展[J]. 临床医学进展, 2026, 16(3): 2438-2445. https://doi.org/10.12677/acm.2026.1631042

参考文献

[1]	He, X., Xie, T., Shi, L., Kuang, X., Li, L., Shang, X., et al. (2025) Research Hotspots and Frontiers in the Tumor Microenvironment of Colorectal Cancer: A Bibliometric Study from 2014 to 2024. Frontiers in Oncology, 15, Article 1525280. [Google Scholar] [CrossRef] [PubMed]
[2]	Hinshaw, D.C. and Shevde, L.A. (2019) The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Research, 79, 4557-4566. [Google Scholar] [CrossRef] [PubMed]
[3]	Li, J., Chen, D. and Shen, M. (2022) Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses. Frontiers in Medicine, 9, Article 869010. [Google Scholar] [CrossRef] [PubMed]
[4]	Krohn, K.A., Link, J.M. and Mason, R.P. (2008) Molecular Imaging of Hypoxia. Journal of Nuclear Medicine, 49, 129S-148S. [Google Scholar] [CrossRef] [PubMed]
[5]	Abu el Maaty, M.A., Terzic, J., Keime, C., Rovito, D., Lutzing, R., Yanushko, D., et al. (2022) Hypoxia-Mediated Stabilization of HIF1A in Prostatic Intraepithelial Neoplasia Promotes Cell Plasticity and Malignant Progression. Science Advances, 8, eabo2295. [Google Scholar] [CrossRef] [PubMed]
[6]	Schito, L. and Rey-Keim, S. (2023) Hypoxia Signaling and Metastatic Progression. Seminars in Cancer Biology, 97, 42-49. [Google Scholar] [CrossRef] [PubMed]
[7]	Zhang, H., Cao, K., Xiang, J., Zhang, M., Zhu, M. and Xi, Q. (2023) Hypoxia Induces Immunosuppression, Metastasis and Drug Resistance in Pancreatic Cancers. Cancer Letters, 571, Article ID: 216345. [Google Scholar] [CrossRef] [PubMed]
[8]	Beckers, C., Pruschy, M. and Vetrugno, I. (2024) Tumor Hypoxia and Radiotherapy: A Major Driver of Resistance Even for Novel Radiotherapy Modalities. Seminars in Cancer Biology, 98, 19-30. [Google Scholar] [CrossRef] [PubMed]
[9]	Abou Khouzam, R., Janji, B., Thiery, J., Zaarour, R.F., Chamseddine, A.N., Mayr, H., et al. (2023) Hypoxia as a Potential Inducer of Immune Tolerance, Tumor Plasticity and a Driver of Tumor Mutational Burden: Impact on Cancer Immunotherapy. Seminars in Cancer Biology, 97, 104-123. [Google Scholar] [CrossRef] [PubMed]
[10]	Chen, K. and Seimbille, Y. (2022) New Developments in Carbonic Anhydrase IX-Targeted Fluorescence and Nuclear Imaging Agents. International Journal of Molecular Sciences, 23, Article 6125. [Google Scholar] [CrossRef] [PubMed]
[11]	Luong-Player, A., Liu, H., Wang, H.L. and Lin, F. (2014) Immunohistochemical Reevaluation of Carbonic Anhydrase IX (CA IX) Expression in Tumors and Normal Tissues. American Journal of Clinical Pathology, 141, 219-225. [Google Scholar] [CrossRef] [PubMed]
[12]	Ronca, R. and Supuran, C.T. (2024) Carbonic Anhydrase IX: An Atypical Target for Innovative Therapies in Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1879, 189120. [Google Scholar] [CrossRef] [PubMed]
[13]	Waheed, A. and Sly, W.S. (2017) Carbonic Anhydrase XII Functions in Health and Disease. Gene, 623, 33-40. [Google Scholar] [CrossRef] [PubMed]
[14]	Courcier, J., de la Taille, A., Nourieh, M., Leguerney, I., Lassau, N. and Ingels, A. (2020) Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management. International Journal of Molecular Sciences, 21, Article 7146. [Google Scholar] [CrossRef] [PubMed]
[15]	Parks, S.K., Chiche, J. and Pouyssegur, J. (2010) Ph Control Mechanisms of Tumor Survival and Growth. Journal of Cellular Physiology, 226, 299-308. [Google Scholar] [CrossRef] [PubMed]
[16]	Parks, S.K., Chiche, J. and Pouysségur, J. (2013) Disrupting Proton Dynamics and Energy Metabolism for Cancer Therapy. Nature Reviews Cancer, 13, 611-623. [Google Scholar] [CrossRef] [PubMed]
[17]	Roussel, E., Capitanio, U., Kutikov, A., Oosterwijk, E., Pedrosa, I., Rowe, S.P., et al. (2022) Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. European Urology, 81, 476-488. [Google Scholar] [CrossRef] [PubMed]
[18]	Hekman, M.C.H., Rijpkema, M., Aarntzen, E.H., Mulder, S.F., Langenhuijsen, J.F., Oosterwijk, E., et al. (2018) Positron Emission Tomography/Computed Tomography with ⁸⁹zr-Girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. European Urology, 74, 257-260. [Google Scholar] [CrossRef] [PubMed]
[19]	Huizing, F.J., Hoeben, B.A.W., Franssen, G., Lok, J., Heskamp, S., Oosterwijk, E., et al. (2017) Preclinical Validation of ¹¹¹In-Girentuximab-F(ab’)₂ as a Tracer to Image Hypoxia Related Marker CAIX Expression in Head and Neck Cancer Xenografts. Radiotherapy and Oncology, 124, 521-525. [Google Scholar] [CrossRef] [PubMed]
[20]	Shuch, B., Pantuck, A.J., Bernhard, J., Morris, M.A., Master, V., Scott, A.M., et al. (2024) [⁸⁹Zr]Zr-Girentuximab for PET-CT Imaging of Clear-Cell Renal Cell Carcinoma: A Prospective, Open-Label, Multicentre, Phase 3 Trial. The Lancet Oncology, 25, 1277-1287. [Google Scholar] [CrossRef] [PubMed]
[21]	Divgi, C.R., Pandit-Taskar, N., Jungbluth, A.A., Reuter, V.E., Gönen, M., Ruan, S., et al. (2007) Preoperative Characterisation of Clear-Cell Renal Carcinoma Using Iodine-124-Labelled Antibody Chimeric G250 (¹²⁴I-cG250) and PET in Patients with Renal Masses: A Phase I Trial. The Lancet Oncology, 8, 304-310. [Google Scholar] [CrossRef] [PubMed]
[22]	Hoeben, B.A.W., Kaanders, J.H.A.M., Franssen, G.M., Troost, E.G.C., Rijken, P.F.J.W., Oosterwijk, E., et al. (2010) PET of Hypoxia with ⁸⁹Zr-Labeled cG250-F(ab’)₂ in Head and Neck Tumors. Journal of Nuclear Medicine, 51, 1076-1083. [Google Scholar] [CrossRef] [PubMed]
[23]	樊珂羽. 碳酸酐酶Ⅸ小分子抑制剂的设计与抗心肌缺血损伤研究[D]: [硕士学位论文]. 南京: 东南大学, 2022.
[24]	Lau, J., Zhang, Z., Jenni, S., Kuo, H., Liu, Z., Vullo, D., et al. (2016) PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with ⁶⁸Ga-Labeled Benzenesulfonamides. Molecular Pharmaceutics, 13, 1137-1146. [Google Scholar] [CrossRef] [PubMed]
[25]	Krall, N., Pretto, F., Mattarella, M., Müller, C. and Neri, D. (2016) A ^99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma in Vivo. Journal of Nuclear Medicine, 57, 943-949. [Google Scholar] [CrossRef] [PubMed]
[26]	Yang, X., Minn, I., Rowe, S.P., Banerjee, S.R., Gorin, M.A., Brummet, M., et al. (2015) Imaging of Carbonic Anhydrase IX with an ¹¹¹In-Labeled Dual-Motif Inhibitor. Oncotarget, 6, 33733-33742. [Google Scholar] [CrossRef] [PubMed]
[27]	Garousi, J., Honarvar, H., Andersson, K.G., Mitran, B., Orlova, A., Buijs, J., et al. (2016) Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase Ix. Molecular Pharmaceutics, 13, 3676-3687. [Google Scholar] [CrossRef] [PubMed]
[28]	Ahlskog, J.K.J., Schliemann, C., Mårlind, J., Qureshi, U., Ammar, A., Pedley, R.B., et al. (2009) Human Monoclonal Antibodies Targeting Carbonic Anhydrase IX for the Molecular Imaging of Hypoxic Regions in Solid Tumours. British Journal of Cancer, 101, 645-657. [Google Scholar] [CrossRef] [PubMed]
[29]	Carlin, S., Khan, N., Ku, T., Longo, V.A., Larson, S.M. and Smith-Jones, P.M. (2010) Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts. PLOS ONE, 5, e10857. [Google Scholar] [CrossRef] [PubMed]
[30]	Massière, F., Wiedemann, N., Borrego, I., Hoehne, A., Osterkamp, F., Paschke, M., et al. (2024) Preclinical Characterization of DPI-4452: A ⁶⁸Ga/¹⁷⁷Lu Theranostic Ligand for Carbonic Anhydrase Ix. Journal of Nuclear Medicine, 65, 761-767. [Google Scholar] [CrossRef] [PubMed]
[31]	Hofman, M.S., Tran, B., Feldman, D.R., Pokorska-Bocci, A., Pichereau, S., Wessen, J., et al. (2024) First-In-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [⁶⁸Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma. Journal of Nuclear Medicine, 65, 740-743. [Google Scholar] [CrossRef] [PubMed]
[32]	Olafsen, T. and Wu, A.M. (2010) Antibody Vectors for Imaging. Seminars in Nuclear Medicine, 40, 167-181. [Google Scholar] [CrossRef] [PubMed]
[33]	Brouwers, A.H., van Eerd, J.E., Frielink, C., et al. (2004) Optimization of Radioimmunotherapy of Renal Cell Carcinoma: Labeling of Monoclonal Antibody cG250 with ¹³¹I, ⁹⁰Y, ¹⁷⁷Lu, or ¹⁸⁶Re. Journal of Nuclear Medicine, 45, 327-337.
[34]	Muselaers, C.H.J., Oosterwijk, E., Bos, D.L., Oyen, W.J.G., Mulders, P.F.A. and Boerman, O.C. (2014) Optimizing Lutetium 177-Anti-Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model. Molecular Imaging, 13, 1-7. [Google Scholar] [CrossRef] [PubMed]
[35]	Brouwers, A.H., Mulders, P.F.A., de Mulder, P.H.M., van den Broek, W.J.M., Buijs, W.C.A.M., Mala, C., et al. (2005) Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy with ¹³¹I-cG250 in Patients with Metastasized Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 23, 6540-6548. [Google Scholar] [CrossRef] [PubMed]
[36]	Divgi, C.R., Bander, N.H., Scott, A.M., et al. (1998) Phase I/II Radioimmunotherapy Trial with Iodine-131-Labeled Monoclonal Anti-Body G250 in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 4, 2729-2739.
[37]	Muselaers, C.H.J., Boerman, O.C., Oosterwijk, E., Langenhuijsen, J.F., Oyen, W.J.G. and Mulders, P.F.A. (2013) Indium-111-Labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma. European Urology, 63, 1101-1106. [Google Scholar] [CrossRef] [PubMed]
[38]	Iikuni, S., Ono, M., Watanabe, H., Shimizu, Y., Sano, K. and Saji, H. (2018) Cancer Radiotheranostics Targeting Carbonic Anhydrase-Ix with ¹¹¹In-and ⁹⁰Y-Labeled Ureidosulfonamide Scaffold for SPECT Imaging and Radionuclide-Based Therapy. Theranostics, 8, 2992-3006. [Google Scholar] [CrossRef] [PubMed]
[39]	Lau, J., Lin, K. and Bénard, F. (2017) Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX. Theranostics, 7, 4322-4339. [Google Scholar] [CrossRef] [PubMed]
[40]	van Dongen, G.A.M.S., Poot, A.J. and Vugts, D.J. (2012) PET Imaging with Radiolabeled Antibodies and Tyrosine Kinase Inhibitors: Immuno-Pet and TKI-PET. Tumor Biology, 33, 607-615. [Google Scholar] [CrossRef] [PubMed]

为你推荐

友情链接